RT Journal Article SR Electronic T1 Cytotoxicty and Radical Modulating Activity of Isoflavones and Isoflavanones from Sophora Species JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1481 OP 1488 VO 24 IS 3A A1 YOSHIAKI SHIRATAKI A1 MARI WAKAE A1 YUKIYO YAMAMOTO A1 KEN HASHIMOTO A1 KAZUE SATOH A1 MARIKO ISHIHARA A1 HIROTAKA KIKUCHI A1 HIROFUMI NISHIKAWA A1 KIMINOBU MINAGAWA A1 NOBORU MOTOHASHI A1 HIROSHI SAKAGAMI YR 2004 UL http://ar.iiarjournals.org/content/24/3A/1481.abstract AB We investigated 2 isoflavones and 9 isoflavanones from Sophora species for their cytotoxic activity against 3 normal human cells (gingival fibroblast, pulp cell, periodontal ligament fibroblast) and 2 human tumor cell lines (squamous cell carcinoma HSC-2, submandibular gland carcinoma HSG). Compounds with 2 isoprenyl groups (one in A-ring and the other in B-ring) such as tetrapterol G [YS31] and isosophoranone [YS24], and those with α, α-dimethylallyl group at C-5’ of B-ring [YS26 (secundifloran), YS27 (secundiflorol A), YS28 (secundiflorol D), YS29 (secundiflorol E)] showed relatively higher cytotoxic activity. When hydrophobicity was assessed by octanol-water partition coefficient (log P), the maximum cytotoxic activity was observed at a log P value around 4. Compounds with intermediate cytotoxic activity [YS27, genistein, YS28, YS29, YS30 (secundiflorol F)] showed relatively higher tumor specificity. All isoflavones and isoflavanones did not stimulate the nitric oxide (NO) production by mouse macrophage-like Raw 264.7 cells, but almost completely inhibited the NO production by lipopolysaccharide (LPS)-activated Raw 264.7 cells. ESR spectroscopy showed that YS26 and YS28, which are the most inhibitory for NO production, efficiently scavenged superoxide anion and NO radicals. These data suggest that the inhibition of macrophage NO production by these isoflavanones may, at least in part, be explained by their radical scavenging or reduction activity. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved